Developer docs
API playgroundTry for free, no card

Search company profiles

eMolecules

Full company profile

uuid0008par

Namestring
eMolecules
Legal namestring
eMolecules, Inc.
Websiteurl
emolecules.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

eMolecules, Inc. operates a chemical search-and-fulfillment platform serving pharmaceutical, biotechnology, academic, and agricultural chemistry researchers. Founded in 2005 in San Diego, the company aggregates a catalog of 83+ million specialty chemistry and biology SKUs from over 300 suppliers across 35 countries, making it the largest readily available chemical inventory accessible through a single digital interface. The platform supports structure-based, substructure, exact, and similarity searches via a proprietary chemical search engine, with a self-serve ecommerce portal at search.emolecules.com and enterprise field sales teams serving 14 of the top 15 global pharmaceutical companies.

The company's product portfolio spans building blocks (9M+ SKUs), screening compounds (24.6M+ SKUs), and biological reagents (6M+ SKUs), supplemented by a virtual chemical space (eXplore) of 8.3+ trillion synthesizable compounds that, following the 2024 Synple Chem AG acquisition, was unified with Synple Space into a 67+ trillion compound virtual library accessible via BioSolveIT's infiniSee platform. The 2024 acquisition also added the Synple2 automated synthesizer, a hardware platform enabling synthesis-on-demand via encapsulated reagent cartridges. Service revenue is generated through compound management, reformatting, storage, and custom chemistry offerings operated from facilities in San Diego, Newark (DE), Cumberland (MD), Stevenage (UK), Zoetermeer (Netherlands), and Kemptthal (Switzerland).

The business model combines transaction-based markups on compound sales, multi-year contracts for compound management services, and recurring subscription access to virtual chemical spaces. Backed by Avista Capital Partners since March 2022, eMolecules has executed a roll-up strategy completing four acquisitions (Frontier Scientific, Frontier Agricultural Sciences, Specs Compound Handling, Synple Chem) between 2022 and 2024, growing to approximately 140 employees across seven global entities. The company sells through enterprise field sales for major pharma, regional inside sales for mid-market and SMB, and a self-serve ecommerce platform, with ongoing geographic expansion into Japan and South Korea and product line diversification into battery chemicals and high-volume essentials.

Short descriptiontext

eMolecules operates a chemical search-and-fulfillment platform for pharmaceutical and biotech drug discovery, aggregating 83+ million SKUs from 300+ suppliers across 35 countries. It serves 14 of the top 15 global pharmaceutical companies and nearly 1,000 total customers with compound procurement, management, virtual screening, and automated synthesis services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
chemical search engine, compound procurement platform, drug discovery reagents, building blocks supply, screening compounds
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery Chemical Marketplace
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Chemical Compound Sales
TypeTransaction Fee
Description

Transaction-based sales of building blocks, screening compounds, and other chemical reagents through the e-commerce platform. Revenue derived from mark-up on compounds sourced from supplier network.

emolecules.com
2Compound Management Services
TypeProfessional Services
Description

Services including compound reformatting, storage, quality control, and management services for pharmaceutical and biotech customers.

emolecules.com
3Custom Chemistry Services
TypeProfessional Services
Description

Custom synthesis and chemistry services including automated synthesis platform and reaction kits.

emolecules.com
4Virtual Compound Access
TypeSubscription Recurring
Description

Access to eXplore virtual chemical space (8.3+ trillion compounds) and Synple virtual library (67 trillion+ compounds) for virtual screening and synthesis-on-demand.

emolecules.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Building Blocks and Screening Compounds
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Pricing varies by compound and supplier. Average cost per eXplore compound is approximately $150 or less. Specific pricing requires quote request.

emolecules.com
2Compound Management Services
ModelOtherBilling cadenceMulti-year contract
Notes

Custom pricing based on service requirements including reformatting, storage, and management needs.

emolecules.com
3Virtual Library Access
ModelSubscriptionBilling cadenceAnnual
Notes

Access to eXplore and Synple virtual chemical spaces requires subscription. Building blocks for DIY synthesis available for purchase per compound.

emolecules.com
GTM typeB2B
B2B
Offering typeDigital Commerce or Conte…
Digital Commerce or Content
Brand1 of 5 records shown
1eXplore
Description

The world's largest commercially available virtual chemical space containing over 8.3 trillion synthesizable compounds, created in collaboration with BioSolveIT.

emolecules.com
+4 more records
Core offering1 text field

eMolecules operates a chemical search-and-fulfillment platform that aggregates over 83 million specialty chemistry and biology SKUs from 300+ suppliers across 35 countries, enabling pharmaceutical and biotech researchers to search, find, and procure building blocks, screening compounds, and biological reagents. The platform combines proprietary structure-search technology, tiered supplier delivery, an 8.3+ trillion compound virtual chemical space (eXplore), automated synthesis systems (Synple2), and integrated compound management services including reformatting, storage, and quality control.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Near-100% reliable on-time delivery
+3 more records
Product overview1 text field

eMolecules operates as a chemical search-and-fulfillment platform providing integrated ecommerce software and services for pharmaceutical, biotechnology, and academic drug discovery research. The platform combines a core product portfolio (Building Blocks with 9M+ compounds, Screening Compounds with 24.6M+ compounds, and Biological Reagents with 6M+ items) with a virtual chemical space (eXplore spanning 8.3+ trillion synthesizable compounds) and automated synthesis solutions (Synple2 synthesizer). The service layer includes compound management, reformatting, storage, quality control, and custom synthesis services, all powered by a chemical search engine with structure-based, similarity, and target-based search capabilities. Recent acquisitions (Frontier Scientific, Specs Compound Handling, Synple Chem) expanded the company into compound management, storage facilities, and automated synthesis services.

Product and service14 records
1Building Blocks
CategoryCore Chemical Catalog
Description

Search and order from over 9 million building block compounds from a global network of trusted suppliers with Tier 1 (1-5 day) and Tier 2 (2-10 day) delivery options for pharmaceutical and biotech drug discovery researchers.

2Screening Compounds
CategoryCore Chemical Catalog
Description

Search and order from over 24.6 million screening compounds for high-throughput drug discovery screening programs serving pharmaceutical and biotech researchers.

3Biological Reagents
CategoryBiological Reagents
Description

Search and order from over 6 million biological reagents including antibodies with detailed target, clonality, host species, and application data for life sciences research.

4eXplore Virtual Chemical Space
CategoryVirtual Chemical Library
Description

World's largest commercially available virtual chemical space with 8.3+ trillion synthesizable compounds built from readily available building blocks using 45 proven reactions, accessible via BioSolveIT infiniSee and providing an average compound cost of approximately $150 or less with 94%+ synthesis success rate.

5eMolecules Essentials
CategoryBranded Product Line
Description

High-volume everyday research chemicals product line designed to streamline sourcing, reduce supplier complexity, and optimize chemical spend without compromising quality.

6Battery Chemicals
CategorySpecialty Chemicals
Description

Specialized battery chemical compounds providing streamlined access to essential compounds driving battery innovation and research for energy storage applications.

7Synple2 Automated Synthesizer
CategoryLaboratory Equipment
Description

Automated chemistry synthesis system enabling chemists to execute complex synthetic processes with a single button press using encapsulated reagent cartridges, providing synthesis-on-demand capabilities for small molecule drug discovery.

8Compound Management Services
CategoryCompound Management Services
Description

Full-service compound management including storage, reformatting, and distribution services for pharmaceutical and biotech screening programs, with facilities in the US (Newark, Cumberland) and Europe (Zoetermeer).

9Reformatting Services
CategoryCompound Management Services
Description

Screening compound reformatting services converting compounds between different plate formats and concentrations for high-throughput screening applications.

10Storage Services
CategoryCompound Management Services
Description

Temperature-controlled compound storage facilities for managing and maintaining chemical compound inventories for pharmaceutical and biotech customers.

11Quality Control Services
CategoryAnalytical Services
Description

Analytical and quality control services ensuring compound identity, purity, and integrity for research and screening compound inventories.

12Custom Chemistry Services
CategoryCustom Synthesis
Description

Custom synthesis services for specialty chemical compounds not available in standard catalogs, serving pharmaceutical, biotechnology, industrial chemical, government, and academic sectors.

13Automated Synthesis Platform Service
CategoryCustom Synthesis
Description

Synthesis-on-demand services using automated chemistry platforms (Synple) for efficient small molecule synthesis serving drug discovery customers.

14Personalized Websites
CategoryCustom Procurement Platform
Description

Custom e-commerce websites tailored to specific customer procurement needs with integrated compound search and ordering functionality.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-13
Description

Partnership announced October 13, 2025 to launch an integrated drug discovery solution combining Pharmacelera's ExaScreen® with eMolecules' eXplore/Synple library. The solution streamlines the process from virtual screening to testing new compounds, accelerating early-stage drug development.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-08-27
Description

Partnership for eXplore virtual chemical space creation and distribution. Synple Space made available across all BioSolveIT platforms and tools. Access via infiniSee chemical space navigation platform.

3Alipheron
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-08-25
Description

Strategic collaboration integrating real-time data from eMolecules' eXplore-Synple virtual space to Alipheron software. Also announced integration of Alipheron's Pharos-3D search technology with the 67 trillion compound Synple-eXplore virtual chemical space in May 2026.

emolecules.com
4Kishida Chemical
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-05-02
Description

Partnership with Kishida Chemical, a highly respected leader in the Japanese chemical supply industry, expanding eMolecules' presence and distribution in Japan.

emolecules.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-04-29
Description

Strategic collaboration formalized through Memorandum of Understanding signed at HITS.ai headquarters in South Korea for AI-driven drug discovery initiatives.

6Knight-Chemicals (Phil Baran)
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-17
Description

New supplier partnership bringing innovative new compounds by Phil Baran to eMolecules' catalog.

emolecules.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-03
Description

Partnership to accelerate AI-powered drug discovery by providing seamless access to eMolecules' chemical library via Optic's BIOPTIC AI platform. Researchers can identify compounds from commercial catalogs using target names or known ligands.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-24
Description

Acquisition of Synple Chem AG strengthens eMolecules' position as global one-stop-shop solution provider. Synple specializes in automated chemical synthesis systems and provides access to 7+ trillion virtual compounds. Combined with eXplore creates 67+ trillion compound virtual library.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-25
Description

Acquisition of Specs Compound Handling B.V. expands eMolecules' compound management capabilities, particularly in Europe. Specs provides chemical compound management services to pharmaceutical, biotechnology and academic sectors with facilities in Netherlands and Maryland, USA.

10Frontier Scientific Inc. and Frontier Agricultural Sciences Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-07
Description

Acquisition of Frontier Scientific Inc. and Frontier Agricultural Sciences Inc. established one-stop shop for chemical compound procurement and management. FSI provides chemical materials management and custom research services; FAS serves entomology research community.

emolecules.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ChemSpace operates an online chemical marketplace aggregating building blocks, screening compounds, and custom synthesis services for drug discovery researchers. It is a direct digital competitor to eMolecules' e-commerce and search platform with overlapping customer base.

TypeEmerging player
Description

BioSolveIT provides chemical space navigation software (infiniSee) and virtual screening tools that integrate with eMolecules' eXplore library. It is a technology partner but also operates in adjacent cheminformatics software space where competitive overlap could grow.

TypeBroad incumbent
Description

Thermo Fisher Scientific offers an extensive portfolio of research chemicals, custom synthesis, and compound management services through its Life Sciences Solutions and Laboratory Products segments. It serves similar pharma/biotech procurement customers at greater scale and with broader instrumentation offerings.

TypeDirect peer
Description

Enamine is a leading European supplier of building blocks, screening compounds, and custom chemistry services, with a similarly large catalog and direct relationships with pharmaceutical discovery teams. It is a direct competitor in compound sourcing and custom synthesis with comparable target customers.

TypeDirect peer
Description

MolPort is a chemical sourcing marketplace that aggregates compounds from multiple suppliers for pharmaceutical and academic researchers. It is a direct peer in the multi-supplier chemical procurement model with comparable search and order platform functionality.

TypeBroad incumbent
Description

WuXi AppTec is a global CRO/CDMO offering compound management, custom synthesis, and drug discovery services to pharmaceutical and biotech customers. It is a broad incumbent in discovery chemistry services with significant overlap to eMolecules' compound management and custom synthesis offerings.

TypeBroad incumbent
Description

MilliporeSigma, the life science business of Merck KGaA, is the world's largest supplier of research chemicals, building blocks, and screening compounds. It is a broad incumbent with overlapping catalog breadth, global distribution, and pharma customer base, though it operates across a much wider life sciences portfolio beyond drug discovery procurement.

TypeDirect peer
Description

Combi-Blocks is a San Diego-based supplier of building blocks and screening compounds serving pharmaceutical, biotech, and academic drug discovery researchers. It is a direct competitor in the building blocks and screening compound supply market with similar customer profiles.

TypeDirect peer
Description

Specs was historically a direct peer offering screening compound libraries and compound management services before being acquired by eMolecules in 2023. It remains relevant as a benchmark for the compound management services segment eMolecules now competes in directly.

TypeEmerging player
Description

Pharmacelera develops computational chemistry and virtual screening software (ExaScreen) and has a formal partnership with eMolecules. It represents an emerging player at the intersection of AI drug discovery and chemical library access where strategic competition or partnership dynamics could shift.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

eMolecules

Drug Discovery Chemical Marketplaceemolecules.com

eMolecules operates a chemical search-and-fulfillment platform for pharmaceutical and biotech drug discovery, aggregating 83+ million SKUs from 300+ suppliers across 35 countries. It serves 14 of the top 15 global pharmaceutical companies and nearly 1,000 total customers with compound procurement, management, virtual screening, and automated synthesis services.

What eMolecules does

eMolecules, Inc. operates a chemical search-and-fulfillment platform serving pharmaceutical, biotechnology, academic, and agricultural chemistry researchers. Founded in 2005 in San Diego, the company aggregates a catalog of 83+ million specialty chemistry and biology SKUs from over 300 suppliers across 35 countries, making it the largest readily available chemical inventory accessible through a single digital interface. The platform supports structure-based, substructure, exact, and similarity searches via a proprietary chemical search engine, with a self-serve ecommerce portal at search.emolecules.com and enterprise field sales teams serving 14 of the top 15 global pharmaceutical companies.

The company's product portfolio spans building blocks (9M+ SKUs), screening compounds (24.6M+ SKUs), and biological reagents (6M+ SKUs), supplemented by a virtual chemical space (eXplore) of 8.3+ trillion synthesizable compounds that, following the 2024 Synple Chem AG acquisition, was unified with Synple Space into a 67+ trillion compound virtual library accessible via BioSolveIT's infiniSee platform. The 2024 acquisition also added the Synple2 automated synthesizer, a hardware platform enabling synthesis-on-demand via encapsulated reagent cartridges. Service revenue is generated through compound management, reformatting, storage, and custom chemistry offerings operated from facilities in San Diego, Newark (DE), Cumberland (MD), Stevenage (UK), Zoetermeer (Netherlands), and Kemptthal (Switzerland).

The business model combines transaction-based markups on compound sales, multi-year contracts for compound management services, and recurring subscription access to virtual chemical spaces. Backed by Avista Capital Partners since March 2022, eMolecules has executed a roll-up strategy completing four acquisitions (Frontier Scientific, Frontier Agricultural Sciences, Specs Compound Handling, Synple Chem) between 2022 and 2024, growing to approximately 140 employees across seven global entities. The company sells through enterprise field sales for major pharma, regional inside sales for mid-market and SMB, and a self-serve ecommerce platform, with ongoing geographic expansion into Japan and South Korea and product line diversification into battery chemicals and high-volume essentials.

eMolecules firmographics

Firmographics
Name
eMolecules
Legal name
eMolecules, Inc.
Website
https://emolecules.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
101–250 employees
Short description
eMolecules operates a chemical search-and-fulfillment platform for pharmaceutical and biotech drug discovery, aggregating 83+ million SKUs from 300+ suppliers across 35 countries. It serves 14 of the top 15 global pharmaceutical companies and nearly 1,000 total customers with compound procurement, management, virtual screening, and automated synthesis services.
Ownership category
akta.pro rank

eMolecules industry classification

Industry
Product category
Drug Discovery Chemical Marketplace
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Chemical search engine
  • Compound procurement platform
  • Drug discovery reagents
  • Building blocks supply
  • Screening compounds

Where eMolecules is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices7 records

Markets served

eMolecules business model

Business model
GTM type
B2B
Offering type
Digital Commerce or Content
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Chemical Compound Sales: Transaction-based sales of building blocks, screening compounds, and other chemical reagents through the e-commerce platform. Revenue derived from mark-up on compounds sourced from supplier network.
  2. Compound Management Services: Services including compound reformatting, storage, quality control, and management services for pharmaceutical and biotech customers.
  3. Custom Chemistry Services: Custom synthesis and chemistry services including automated synthesis platform and reaction kits.
  4. Virtual Compound Access: Access to eXplore virtual chemical space (8.3+ trillion compounds) and Synple virtual library (67 trillion+ compounds) for virtual screening and synthesis-on-demand.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goBuilding Blocks and Screening Compounds
OtherMulti-year contractCompound Management Services
SubscriptionAnnualVirtual Library Access

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

eMolecules product offering

Product offering

Core offering

eMolecules operates a chemical search-and-fulfillment platform that aggregates over 83 million specialty chemistry and biology SKUs from 300+ suppliers across 35 countries, enabling pharmaceutical and biotech researchers to search, find, and procure building blocks, screening compounds, and biological reagents. The platform combines proprietary structure-search technology, tiered supplier delivery, an 8.3+ trillion compound virtual chemical space (eXplore), automated synthesis systems (Synple2), and integrated compound management services including reformatting, storage, and quality control.

Product overview

eMolecules operates as a chemical search-and-fulfillment platform providing integrated ecommerce software and services for pharmaceutical, biotechnology, and academic drug discovery research. The platform combines a core product portfolio (Building Blocks with 9M+ compounds, Screening Compounds with 24.6M+ compounds, and Biological Reagents with 6M+ items) with a virtual chemical space (eXplore spanning 8.3+ trillion synthesizable compounds) and automated synthesis solutions (Synple2 synthesizer). The service layer includes compound management, reformatting, storage, quality control, and custom synthesis services, all powered by a chemical search engine with structure-based, similarity, and target-based search capabilities. Recent acquisitions (Frontier Scientific, Specs Compound Handling, Synple Chem) expanded the company into compound management, storage facilities, and automated synthesis services.

Differentiator

Problem solved

Functional benefit

Brands

  • eXplore: The world's largest commercially available virtual chemical space containing over 8.3 trillion synthesizable compounds, created in collaboration with BioSolveIT.
  • Synple Space
  • eMolecules Essentials
  • Battery Chemicals
  • Synple2

Products and services

  • Building Blocks Search and order from over 9 million building block compounds from a global network of trusted suppliers with Tier 1 (1-5 day) and Tier 2 (2-10 day) delivery options for pharmaceutical and biotech drug discovery researchers.
  • Screening Compounds Search and order from over 24.6 million screening compounds for high-throughput drug discovery screening programs serving pharmaceutical and biotech researchers.
  • Biological Reagents Search and order from over 6 million biological reagents including antibodies with detailed target, clonality, host species, and application data for life sciences research.
  • eXplore Virtual Chemical Space World's largest commercially available virtual chemical space with 8.3+ trillion synthesizable compounds built from readily available building blocks using 45 proven reactions, accessible via BioSolveIT infiniSee and providing an average compound cost of approximately $150 or less with 94%+ synthesis success rate.
  • eMolecules Essentials High-volume everyday research chemicals product line designed to streamline sourcing, reduce supplier complexity, and optimize chemical spend without compromising quality.
  • Battery Chemicals Specialized battery chemical compounds providing streamlined access to essential compounds driving battery innovation and research for energy storage applications.
  • Synple2 Automated Synthesizer Automated chemistry synthesis system enabling chemists to execute complex synthetic processes with a single button press using encapsulated reagent cartridges, providing synthesis-on-demand capabilities for small molecule drug discovery.
  • Compound Management Services Full-service compound management including storage, reformatting, and distribution services for pharmaceutical and biotech screening programs, with facilities in the US (Newark, Cumberland) and Europe (Zoetermeer).
  • Reformatting Services Screening compound reformatting services converting compounds between different plate formats and concentrations for high-throughput screening applications.
  • Storage Services Temperature-controlled compound storage facilities for managing and maintaining chemical compound inventories for pharmaceutical and biotech customers.
  • Quality Control Services Analytical and quality control services ensuring compound identity, purity, and integrity for research and screening compound inventories.
  • Custom Chemistry Services Custom synthesis services for specialty chemical compounds not available in standard catalogs, serving pharmaceutical, biotechnology, industrial chemical, government, and academic sectors.
  • Automated Synthesis Platform Service Synthesis-on-demand services using automated chemistry platforms (Synple) for efficient small molecule synthesis serving drug discovery customers.
  • Personalized Websites Custom e-commerce websites tailored to specific customer procurement needs with integrated compound search and ordering functionality.

Quantifiable outcome

  • Near-100% reliable on-time delivery
  • +3 more outcomes

Companies that use eMolecules

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

eMolecules technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability7 records

Feature5 records

eMolecules partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • PharmaceleracoreTechnology or Integration · 13 October 2025Partnership announced October 13, 2025 to launch an integrated drug discovery solution combining Pharmacelera's ExaScreen® with eMolecules' eXplore/Synple library. The solution streamlines the process from virtual screening to testing new compounds, accelerating early-stage drug development.
  • BioSolveITcoreTechnology or Integration · 27 August 2025Partnership for eXplore virtual chemical space creation and distribution. Synple Space made available across all BioSolveIT platforms and tools. Access via infiniSee chemical space navigation platform.
  • AlipheroncoreTechnology or Integration · 25 August 2025Strategic collaboration integrating real-time data from eMolecules' eXplore-Synple virtual space to Alipheron software. Also announced integration of Alipheron's Pharos-3D search technology with the 67 trillion compound Synple-eXplore virtual chemical space in May 2026.
  • Kishida ChemicalcoreChannel Partner/ Reseller/ Distributor · 2 May 2025Partnership with Kishida Chemical, a highly respected leader in the Japanese chemical supply industry, expanding eMolecules' presence and distribution in Japan.
  • HITS.aiminorStrategic or Co-development Partner · 29 April 2025Strategic collaboration formalized through Memorandum of Understanding signed at HITS.ai headquarters in South Korea for AI-driven drug discovery initiatives.
  • Knight-Chemicals (Phil Baran)minorChannel Partner/ Reseller/ Distributor · 17 April 2025New supplier partnership bringing innovative new compounds by Phil Baran to eMolecules' catalog.
  • OpticcoreTechnology or Integration · 3 October 2024Partnership to accelerate AI-powered drug discovery by providing seamless access to eMolecules' chemical library via Optic's BIOPTIC AI platform. Researchers can identify compounds from commercial catalogs using target names or known ligands.
  • Synple Chem AGcoreStrategic or Co-development Partner · 24 September 2024Acquisition of Synple Chem AG strengthens eMolecules' position as global one-stop-shop solution provider. Synple specializes in automated chemical synthesis systems and provides access to 7+ trillion virtual compounds. Combined with eXplore creates 67+ trillion compound virtual library.
  • Specs Compound Handling B.V.coreStrategic or Co-development Partner · 25 May 2023Acquisition of Specs Compound Handling B.V. expands eMolecules' compound management capabilities, particularly in Europe. Specs provides chemical compound management services to pharmaceutical, biotechnology and academic sectors with facilities in Netherlands and Maryland, USA.
  • Frontier Scientific Inc. and Frontier Agricultural Sciences Inc.coreStrategic or Co-development Partner · 7 September 2022Acquisition of Frontier Scientific Inc. and Frontier Agricultural Sciences Inc. established one-stop shop for chemical compound procurement and management. FSI provides chemical materials management and custom research services; FAS serves entomology research community.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

eMolecules competitors and assessment

Company assessment

Direct peers

  • ChemSpace: ChemSpace operates an online chemical marketplace aggregating building blocks, screening compounds, and custom synthesis services for drug discovery researchers. It is a direct digital competitor to eMolecules' e-commerce and search platform with overlapping customer base.
  • Enamine: Enamine is a leading European supplier of building blocks, screening compounds, and custom chemistry services, with a similarly large catalog and direct relationships with pharmaceutical discovery teams. It is a direct competitor in compound sourcing and custom synthesis with comparable target customers.
  • MolPort: MolPort is a chemical sourcing marketplace that aggregates compounds from multiple suppliers for pharmaceutical and academic researchers. It is a direct peer in the multi-supplier chemical procurement model with comparable search and order platform functionality.
  • Combi-Blocks: Combi-Blocks is a San Diego-based supplier of building blocks and screening compounds serving pharmaceutical, biotech, and academic drug discovery researchers. It is a direct competitor in the building blocks and screening compound supply market with similar customer profiles.
  • Specs (now part of eMolecules): Specs was historically a direct peer offering screening compound libraries and compound management services before being acquired by eMolecules in 2023. It remains relevant as a benchmark for the compound management services segment eMolecules now competes in directly.

Emerging players

  • BioSolveIT: BioSolveIT provides chemical space navigation software (infiniSee) and virtual screening tools that integrate with eMolecules' eXplore library. It is a technology partner but also operates in adjacent cheminformatics software space where competitive overlap could grow.
  • Pharmacelera: Pharmacelera develops computational chemistry and virtual screening software (ExaScreen) and has a formal partnership with eMolecules. It represents an emerging player at the intersection of AI drug discovery and chemical library access where strategic competition or partnership dynamics could shift.

Broad incumbents

  • Thermo Fisher Scientific: Thermo Fisher Scientific offers an extensive portfolio of research chemicals, custom synthesis, and compound management services through its Life Sciences Solutions and Laboratory Products segments. It serves similar pharma/biotech procurement customers at greater scale and with broader instrumentation offerings.
  • WuXi AppTec: WuXi AppTec is a global CRO/CDMO offering compound management, custom synthesis, and drug discovery services to pharmaceutical and biotech customers. It is a broad incumbent in discovery chemistry services with significant overlap to eMolecules' compound management and custom synthesis offerings.
  • Sigma-Aldrich (MilliporeSigma / Merck KGaA): MilliporeSigma, the life science business of Merck KGaA, is the world's largest supplier of research chemicals, building blocks, and screening compounds. It is a broad incumbent with overlapping catalog breadth, global distribution, and pharma customer base, though it operates across a much wider life sciences portfolio beyond drug discovery procurement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

eMolecules social profiles

Digital presence

eMolecules compliance and trust

Trust signal

Compliance7 records

eMolecules financial estimates

Financial estimate

Revenue estimate

Valuation estimate

eMolecules leadership team

Management profile

Number of profiles

Profiles3 records

eMolecules subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

eMolecules funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

eMolecules M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about eMolecules

What does eMolecules do?

eMolecules operates a chemical search-and-fulfillment platform that aggregates over 83 million specialty chemistry and biology SKUs from 300+ suppliers across 35 countries, enabling pharmaceutical and biotech researchers to search, find, and procure building blocks, screening compounds, and biological reagents. The platform combines proprietary structure-search technology, tiered supplier delivery, an 8.3+ trillion compound virtual chemical space (eXplore), automated synthesis systems (Synple2), and integrated compound management services including reformatting, storage, and quality control.

Is eMolecules a public or private company?

eMolecules is a private company. It is classified as private equity controlled and is currently operating.

When was eMolecules founded?

eMolecules was founded in 2005. It employs 101 to 250 people.

Where is eMolecules based?

eMolecules is headquartered in San Diego, United States, in the North America region.

How does eMolecules make money?

Four revenue lines are on record. Chemical Compound Sales are the primary driver. The others are compound Management Services, custom Chemistry Services and virtual Compound Access.

Who are eMolecules's main competitors?

Direct peers on record are ChemSpace, Enamine, MolPort, Combi-Blocks and Specs (now part of eMolecules). Emerging players are BioSolveIT and Pharmacelera. Broad incumbents are Thermo Fisher Scientific, WuXi AppTec and Sigma-Aldrich (MilliporeSigma / Merck KGaA).

Does eMolecules have an API?

No public API is recorded for eMolecules.

What industry is eMolecules in?

eMolecules's product category is Drug Discovery Chemical Marketplace. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireAsedaSciences® and eMolecules Partner to Integrate Professional Compound Management Services into the 3RnD® PlatformAsedaSciences and eMolecules announced a strategic agreement to integrate eMolecules' Frontier Scientific compound management services into the 3RnD platform. The partnership covers storage, preparation, aliquoting, quality control, and inventory management, aiming to improve data quality and reproducibility in chemical R&D.PharmaceleraPharmacelera and eMolecules Launch Integrated Solution for Faster Hit DiscoveryPharmacelera and eMolecules announced the launch of an integrated solution combining Pharmacelera's ExaScreen® Quantum-Mechanics and Machine Learning algorithms with eMolecules' eXplore/Synple curated compound library for early-stage drug discovery. The partnership provides researchers with an end-to-end workflow from computational predictions to physical compound samples, enabling rapid identification, sourcing, and testing of novel chemical matter. Both companies positioned this as a strategic alignment combining computational precision with practical compound access for accelerating hit discovery.EmoleculesPharmacelera and eMolecules launch collaborationPharmacelera and eMolecules announced a partnership to launch an integrated solution combining Pharmacelera's ExaScreen® with eMolecules' eXplore/Synple library for early-stage drug discovery. The collaboration enables researchers to navigate chemical space efficiently while ensuring synthetic feasibility, combining quantum-mechanics and machine-learning-driven algorithms with curated synthetically tractable compounds. The solution provides an end-to-end workflow from computational predictions to physical sample validation, accelerating the path from virtual screening to experimental testing.YahooeMolecules and Optic Join Forces to Accelerate Drugs' Time-to-MarketeMolecules and Optic partnered to accelerate AI-powered drug discovery via BIOPTIC, giving researchers access to eMolecules' library of over 20 million in-stock compounds and 55 million virtual compounds. The platform aims to streamline compound identification and delivery, addressing the 10-15 year average drug development timeline and $2.8 billion cost.BioSpaceeMolecules Acquires Synple Chem AGeMolecules, Inc. has acquired Synple Chem AG to expand its product portfolio with automated chemical synthesis systems and access to a vast virtual compound library. This strategic move combines eMolecules' search-and-fulfillment platform with Synple's technology to create a comprehensive one-stop-shop solution for drug discovery researchers in the United States and Europe.EmoleculesSpecs News AnnouncementeMolecules, Inc. announced the acquisition of Specs Compound Handling B.V. on May 25, 2023, expanding its footprint in global chemical compound procurement and management services aimed at drug discovery researchers. The acquisition enhances eMolecules' capabilities and aims to support efficient procurement and management across distributed chemistry groups. This strategic move is expected to provide operational returns for clients in the pharmaceutical and biotechnology sectors.SpecsCompound Management services and Research Compounds for the Life Science industryeMolecules, Inc. has acquired Specs Compound Handling B.V., a leading provider of chemical compound management services based in the Netherlands. This acquisition expands eMolecules' global footprint, integrating Specs' European operations with eMolecules' US and Asian capabilities to offer a comprehensive solution for drug discovery researchers.PR NewswireeMolecules acquires Frontier Scientific Inc. and Frontier Agricultural Sciences Inc.eMolecules announced the acquisition of Frontier Scientific Inc. and Frontier Agricultural Sciences Inc. to expand its chemistry search-and-fulfillment platform capabilities. The combination creates a comprehensive solution for chemical compound procurement, allowing eMolecules to enter the agricultural chemistry market while integrating the acquired companies' teams into their Newark, Delaware operations.PR NewswireAvista Capital Makes Investment in eMoleculesAvista Capital Partners signed a definitive agreement to invest in eMolecules, an e-procurement platform for high-value chemicals and bioreagents used in pharmaceutical drug discovery. Financial terms were not disclosed. The investment aims to support eMolecules' growth among its existing base of pharmaceutical customers and expansion into other biopharma and academic markets.PR NewswireeMolecules refuerza sus equipos de relaciones estratégicas con clientes y proveedoreseMolecules announced the appointment of three senior executives to strengthen its strategic partnerships and procurement functions. Paul Burke joins as VP of Procurement from Novartis, while Kemberlyn Wuerfel and Paul Edgard Clémençon join as VPs of Strategic Partnerships for the US and Europe respectively, bringing backgrounds from Thermo Fisher and VWR. The hires aim to enhance the company's supply chain and customer relationship capabilities across pharmaceutical, biotech, academic, and agrochemical sectors.